Pfizer will invest $25 million into Monogram Biosciences and will collaborate on Monogram's Co-Receptor Tropism Assay. The Co-Receptor Tropism Assay has been utilized in HIV/AIDS clinical trials for Pfizer's investigational CCR5 inhibitor drug candidate, maraviroc.
"Monogram and Pfizer have had an outstanding business relationship for a number of years," says William D. Young, Monogram CEO. "In 2002, Pfizer made an equity investment in Monogram and since that time, we have provided sophisticated molecular diagnostic testing services and scientific assistance in the area of HIV drug resistance for many of Pfizer's HIV programs, including the ongoing Phase III maraviroc clinical development program."
- read the release on the deal